PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.\', \'Data Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands.\', \'Bordeaux PharmacoEpi, University of Bordeaux, Bordeaux, France.\', \'Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.\', \'Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1002/pds.5029
?:hasPublicationType
?:journal
  • Pharmacoepidemiology and drug safety
is ?:pmid of
?:pmid
?:pmid
  • 32369865
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.329
?:rankingScore_hIndex
  • 80
?:title
  • Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32369865>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32369865>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all